Nano-Targeted Delivery of Toremifene, an Estrogen Receptor-α Blocker in Prostate Cancer

[1]  A. D'Amico,et al.  Association of androgen‐deprivation therapy with excess cardiac‐specific mortality in men with prostate cancer , 2015, BJU international.

[2]  K. Nakagawa,et al.  Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer , 2015, International Journal of Clinical Oncology.

[3]  D. Peiffert,et al.  Niveaux de preuve des nouvelles techniques de radiothérapie du cancer de la prostate , 2014 .

[4]  P. Nelson,et al.  Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes , 2014, PloS one.

[5]  E. Basch,et al.  Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. , 2014, The Lancet. Oncology.

[6]  J. Cheville,et al.  Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy , 2014, Prostate Cancer and Prostatic Disease.

[7]  Wen-Jeng Wu,et al.  Clinical predictor of survival following docetaxel-based chemotherapy , 2014, Oncology letters.

[8]  B. Ristau,et al.  The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. , 2014, Urologic oncology.

[9]  S. Mousa,et al.  Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. , 2013, Nanomedicine.

[10]  M. Stöckle,et al.  ICRAC controls the rapid androgen response in human primary prostate epithelial cells and is altered in prostate cancer , 2013, Oncotarget.

[11]  Xuan Zhang,et al.  New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells. , 2012, International journal of oncology.

[12]  Omid C. Farokhzad,et al.  α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. , 2012, ACS nano.

[13]  Y. Bansal,et al.  MS2/TOF and LC-MS/TOF studies on toremifene to characterize its forced degradation products. , 2011, The Analyst.

[14]  S. Tagawa,et al.  Prostate-Specific Membrane Antigen-Based Therapeutics , 2011, Advances in urology.

[15]  S. Mousa,et al.  Nanotechnology-Based Detection and Targeted Therapy in Cancer: Nano-Bio Paradigms and Applications , 2011, Cancers.

[16]  Hong Xu,et al.  Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment. , 2010, ACS nano.

[17]  Shaker A. Mousa,et al.  Cancer Detection and Treatment: The Role of Nanomedicines , 2009, Molecular biotechnology.

[18]  H. Bonkhoff,et al.  The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. , 2009, European urology.

[19]  X. de la Torre,et al.  A Mass Spectrometric Approach for the Study of the Metabolism of Clomiphene, Tamoxifen and Toremifene by Liquid Chromatography Time-of-Flight Spectroscopy , 2008, European journal of mass spectrometry.

[20]  D. Bostwick,et al.  Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. , 2006, The Journal of urology.

[21]  F. Marshall,et al.  In vivo molecular and cellular imaging with quantum dots. , 2005, Current opinion in biotechnology.

[22]  P. Carroll,et al.  The relative impact and future burden of prostate cancer in the United States. , 2004, The Journal of urology.

[23]  J. Gustafsson,et al.  Estrogen signaling: a subtle balance between ER alpha and ER beta. , 2003, Molecular interventions.

[24]  Seong-Jin Kim,et al.  Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. , 2002, Cancer research.

[25]  M. Steiner,et al.  Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. , 2002, Cancer research.

[26]  R L Sokoloff,et al.  A dual‐monoclonal sandwich assay for prostate‐specific membrane antigen: Levels in tissues, seminal fluid and urine , 2000, The Prostate.

[27]  George L. Wright,et al.  Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.

[28]  W. Fair,et al.  Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. , 1995, Cancer research.

[29]  W. L. Davis,et al.  Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. , 1990, Cancer research.

[30]  D. Peiffert,et al.  [What is the level of evidence of new techniques in prostate cancer radiotherapy?]. , 2014, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[31]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[32]  V. Sumantran.  Cellular chemosensitivity assays: an overview. , 2011, Methods in molecular biology.

[33]  Wang Xing-sheng,et al.  Overview of Prostate-specific Membrane Antigen , 2010 .

[34]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.